Piramal Pharma could get a lift as drugmakers look to spread manufacturing away from single regions and as demand grows for specialized outsourced production, especially for newer cancer medicines. The big question is whether new capacity and customer wins arrive fast enough to offset uneven biotech spending, concentrated clients, and tougher competition in hospital drugs.Read more
Piramal Pharma is building more production capacity and leaning into complex drug manufacturing as more companies outsource and global demand for medicines rises. But its growth story depends on a few big customers and steady rules and pricing in key markets, which could quickly change the outlook.Read more
Catalysts About Piramal Pharma Piramal Pharma operates a diversified pharmaceuticals platform spanning CDMO services, complex hospital generics and consumer healthcare brands. What are the underlying business or industry changes driving this perspective?Read more
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids’ wellness, digestives, and women’s health, as well as geriatric care. The company was incorporated in 2020 and is based in Mumbai, India.
